Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Gatterbauer, B; Hirschmann, D; Eberherr, N; Untersteiner, H; Cho, A; Shaltout, A; Göbl, P; Fitschek, F; Dorfer, C; Wolfsberger, S; Kasprian, G; Höller, C; Frischer, JM.
Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Cancer Med. 2020; 9(11):4026-4036
Doi: 10.1002/cam4.3021
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Wolfsberger Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND: Few safety data of concurrent stereotactic radiosurgery and targeted therapy (TT) or immunotherapy (IT) are available. The aim of the study was to evaluate the outcome of melanoma patients with brain metastases (MBM) after Gamma Knife Radiosurgery (GKRS) in relation to IT/TT. METHODS: We evaluated 182 MBM patients, who were treated with GKRS in the modern radiosurgical and oncological era. RESULTS: The median time between the initial melanoma diagnosis and occurrence of MBM was 2.4 years. The median overall survival time was 5.4 years after melanoma diagnosis. The estimated median survival after the initial diagnosis of MBM was 1.0 year (95% CI = 0.7-1.2 years). Patients treated with anti-PD-1 or a combination of anti-CTLA-4/PD-1 showed a significantly longer survival after first GKRS compared to all other forms of treatment. In addition, patients treated with anti-PD-1, anti-CTLA-4, or a combination of anti-CTLA-4/PD-1 showed a significantly longer time to new MBM after GKRS1 compared to patients treated with other forms and combinations of the oncological therapy. The occurrence of hemorrhage or radiation reaction/necrosis after GKRS did not show any statistically significant differences in relation to IT/TT. CONCLUSION: In MBM patients, complications after GKRS are not significantly increased if IT/TT treatment is performed at the time of or after radiosurgery. Further, a clear benefit in distant control and survival is seen in MBM patients treated with GKRS and checkpoint inhibitors. Thus, concomitant treatment of MBM with GKRS and IT/TT seems to be a safe and powerful treatment option although further prospective studies should be conducted.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult - administration & dosage
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Austria - epidemiology
- Brain Neoplasms - immunology, metabolism, secondary, therapy
- CTLA-4 Antigen - antagonists & inhibitors, immunology
- Combined Modality Therapy - administration & dosage
- Drug-Related Side Effects and Adverse Reactions - epidemiology, etiology, pathology
- Female - administration & dosage
- Follow-Up Studies - administration & dosage
- Humans - administration & dosage
- Immune Checkpoint Inhibitors - adverse effects
- Immunotherapy - adverse effects, mortality
- Male - administration & dosage
- Melanoma - immunology, metabolism, pathology, therapy
- Middle Aged - administration & dosage
- Molecular Targeted Therapy - administration & dosage
- Prognosis - administration & dosage
- Programmed Cell Death 1 Receptor - antagonists & inhibitors, immunology
- Radiation Tolerance - administration & dosage
- Radiosurgery - adverse effects, mortality
- Retrospective Studies - administration & dosage
- Survival Rate - administration & dosage
- Find related publications in this database (Keywords)
- brain metastases
- gamma knife radiosurgery
- immunotherapy
- melanoma
- targeted therapy